Adocia - ADOCY STOCK NEWS

Adocia, a biopharmaceutical company focused on diabetes treatment, reported a cash position of nearly 14 million euros as of March 31, 2023, down from 17.4 million euros at the end of 2022. The company has initiated negotiations with lenders to adjust financial covenants to extend its cash horizon, indicating potential liquidity concerns. For Q1 2023, total revenues increased to 812,000 euros from 580,000 euros in Q1 2022, primarily driven by licensing and collaboration agreements. The flagship product, M1Pram, is in advanced partnership negotiations, which could significantly enhance future cash flow. Adocia aims to achieve financial stability through partnerships and monetization of royalties while exploring opportunities within their pipeline, including ongoing studies for AdoShell^® and BioChaperone^® projects.

Adocia, a clinical-stage biopharmaceutical company specializing in diabetes and metabolic disease treatments, announced its annual shareholders' meeting scheduled for May 11, 2023, at 10.00 am in Paris. The meeting notice was published on April 5, 2023, and includes the agenda, proposed resolutions, and participation instructions. Shareholders must register their shares two business days prior to the meeting. Documentation related to the meeting is available on Adocia's website. Adocia holds over 25 patent families and has developed technologies like BioChaperone^® for insulin products and AdOral^® for oral peptide delivery. The company was ranked among the top SMEs in patent filings in France in recent years and employs approximately 115 people.

Adocia reported its annual financial results for 2022, highlighting significant improvements. The net loss narrowed to €6.9m from €22.8m in 2021. Revenues surged to €11.4m, primarily due to milestone achievements in partnerships with Tonghua Dongbao. Operating expenses rose to €30.2m, but the company holds a cash position of €17.4m, which sustains operations until September 2023. Major advancements include entering phase 3 for BioChaperone® Lispro in China and positive phase 2 results for M1Pram, attracting potential licensing deals.

Adocia, a biopharmaceutical company based in Lyon, France, has published its January 2023 Letter to Shareholders. The company focuses on innovative therapies for diabetes and metabolic diseases, leveraging proprietary technologies such as BioChaperone® and AdOral®. Adocia holds over 25 patent families and employs approximately 100 people.

The press release includes cautionary forward-looking statements and highlights the company's commitment to addressing risks in research and development. Adocia is listed on the Euronext Paris under the ticker ADOC.

Adocia (Euronext: ADOC) released a liquidity report detailing its account as of December 31, 2022. The report showed a cash balance of €128,567.86 and 28,970 shares. In the second half of 2022, there were 79,644 shares purchased for €317,995.49 across 345 transactions, while 83,395 shares were sold for €347,954.16 in 366 transactions. The liquidity agreement adheres to AMF Decision n° 2021-01, aimed at enhancing market liquidity. Founded in Lyon, Adocia specializes in metabolic disease solutions, particularly diabetes and obesity, leveraging multiple proprietary technology platforms.